Hangzhou Tigermed Consulting Co., Ltd (SHE:300347)

Market Cap	51.99B +24.7%
Revenue (ttm)	6.56B -3.5%
Net Income	612.15M -36.1%
EPS	0.71 -35.6%
Shares Out	855.14M
PE Ratio	88.50
Forward PE	63.19
Dividend	0.30 (0.50%)
Ex-Dividend Date	Jun 17, 2025

Volume	16,977,256
Average Volume	12,745,425
Open	60.08
Previous Close	63.20
Day's Range	60.08 - 65.59
52-Week Range	41.61 - 71.90
Beta	0.65
RSI	61.94
Earnings Date	Mar 31, 2026

About SHE:300347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 10,251
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300347

Financial Performance

In 2024, SHE:300347's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.